Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: A meta-regression analysis of randomized trials

American Heart Journal

Volumn 167, Issue 3, 2014, Pages

  Tarantini, Giuseppe ^a   Brener, Sorin Jakob ^b   Barioli, Alberto ^a   Gratta, Andrea ^a   Parodi, Guido ^c   Rossini, Roberta ^d   Navarese, Eliano Pio ^e   Niccoli, Giampaolo ^f   Frigo, Anna Chiara ^a   Musumeci, Giuseppe ^d   Iliceto, Sabino ^a   Stone, Gregg Whitney ^g  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b NEW YORK METHODIST HOSPITAL   (United States)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG;

ARTICLE; BLEEDING; COCHRANE LIBRARY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEART INFARCTION; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ANTITHROMBINS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84896875874     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.11.013     Document Type: Article

References (38)

1. J.A. Bittl, B.R. Chaitman, and F. Feit et al. Bivalirudin versus heparin during angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study Am Heart J 142 2001 952 959
2. A.M. Lincoff, J.A. Bittl, N.S. Kleiman REPLACE-1 Investigators Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol 93 2004 1092 1096
3. A.M. Lincoff, J.A. Bittl, R.A. Harrington REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
4. G.W. Stone, H.D. White, E.M. Ohman Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial Lancet 369 2007 907 919
5. A. Kastrati, F.J. Neumann, J. Mehilli ISAR-REACT 3 Trial Investigators Bivalirudin versus unfractionated heparin during percutaneous intervention N Eng J Med 359 2008 688 696
6. A. Kastrati, F.J. Neumann, S. Schulz ISAR-REACT 4 Trial Investigators Abciximab and heparin versus bivalirudin for non-ST myocardial infarction N Engl J Med 365 2011 1980 1989
7. G.W. Stone, B. Witzenbichler, G. Guagliumi HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
8. G.W. Stone, B. Witzenbichler, G. Guagliumi HORIZONS-AMI Trial Investigators Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377 9784 2011 2193 2204
9. R. Mehran, S. Pocock, and E. Nikolsky et al. Impact of bleeding on mortality after percutaneous coronary intervention JACC 4 2011 654 664
10. D.J. Moliterno TENACITY Trial Investigators A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The Tirofiban Evaluation of Novel Dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin (TENACITY) Study Trial Catheter Cardiovasc Interv 77 2011 1001 1009
11. N.V. Deshpande, R. Pratiti, and P. Admane et al. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention Indian Heart J 64 5 2012 444 448
12. R. Waksman, O. Bertrand, and M. Driesman et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III) J Interv Cardiol 26 2 2013 107 113
13. A.M. Lincoff, N.S. Kleiman, and K. Kottke-Marchant et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of comparison of Abciximab Complications with Hirulog for Ischemic Event Trial (CACHET) Am Heart J 143 2002 847 853
14. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Cochrane Collaboration, 2011.
15. C.H. Schmid, J. Lau, and M.W. McIntosh et al. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials Stat Med 17 1998 1923 1942
16. G. Tarantini, R. Razzolini, and M. Napodano et al. Acceptable reperfusion delay to prefer primary angioplasty over fibrin-specific thrombolytic therapy is affected (mainly) by the patient's mortality risk: 1 h does not fit all Eur Heart J 31 6 2010 676 683
17. S.V. Manoukian The relationship between bleeding and adverse outcome in ACS and PCI: pharmacologic and nonpharmacologic modification of risk J Invasive Cardiol 22 3 2010 132 141
18. S.V. Manoukian, F. Feit, and R. Mehran et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from ACUITY trial J Am Coll Cardiol 49 2007 1362 1368
19. T.D. Kinnaird, E. Stabile, and G.S. Mintz et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 2003 930 935
20. S.V. Rao, K. O'Grady, and K.S. Pieper et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 2005 1200 1206
21. G. De Luca, and P. Marino Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials Am Heart J 154 2007 1085el 1086el
22. G. Parodi, A. Migliorini, and R. Valenti et al. A randomized trial comparing bivalirudin with unfractionated heparin in patients undergoing elective PCI (ARNO trial) Am J Cardiol 105 8 2010 1053 1059
23. D. Tavano, G. Visconti, and D. D'Andrea et al. Randomized comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in diabetic patients undergoing elective coronary stenting Am J Cardiol 104 9 2009 1222 1228
24. G. Patti, V. Pasceri, and L. D'Antonio et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs. Heparin Study) Am J Cardiol 110 2012 478 484
25. C.M. Gibson, D.A. Morrow, and S.A. Murphy et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 12 2006 2364 2373
26. A.J. Chase, E.B. Fretz, and W.P. Warburton et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefits Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) Heart 94 2008 1019 1025
27. W.J. Cantor, K.W. Mahaffey, and Z. Huang et al. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal Catheter Cardiovasc Interv 69 2007 73 83
28. J. Ducas, M.C. Chan, and A. Miller et al. Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 249 patients Catheter Cardiovasc Interv 56 2002 196 199
29. F.S. Resnic, T.Y. Wang, and N. Arora et al. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (NationalCardiovascular Data Registry) CathPCI registry JACC Cardiovasc Interv 5 1 2012 82 89
30. F.W. Verheugt, S.R. Steinhubl, and M. Hamon et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention JACC Cardiovasc Interv 4 2 2011 191 197
31. M. Hamon, L.H. Rasmussen, and S.V. Manoukian et al. Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial EuroIntervention 5 1 2009 115 120
32. F. Feit, M.D. Voeltz, and M.J. Attubato et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial Am J Cardiol 100 2007 1364 1369
33. F.A. Spencer, M. Moscucci, C.B. Granger GRACE Investigators Does comorbidity account for the excess mortality in patients with major bleeding in acute coronary infarction? Circulation 116 2007 2793 2801
34. Fifth organization to assess strategies in acute ischemic syndromes investigators S. Yusuf, and S.R. Mehta et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Eng J Med 354 2006 1464 1476
35. D.A. Morrow Antithrombotic therapy to support primary PCI N Engl J Med 358 2008 2280 2282
36. B.J. Doyle, C.S. Rihal, and D.A. Gastineau et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice J Am Coll Cardiol 53 2009 2019 2027
37. S.V. Rao, J.A. Eikelboom, and C.B. Granger et al. Bleeding and blood transfusion issues in patients with non-ST-segment evaluation acute coronary syndromes Eur Heart J 28 2007 1193 1204
38. S.V. Rao, J.G. Jollis, and R.A. Harrington et al. The relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562